Minerva Neurosciences Inc. sell geldnutzer
Start price
22.12.20
/
50%
€16.64
Target price
22.12.21
€14.40
Performance (%)
40.38%
End price
20.02.21
€23.36
Summary
This prediction ended on 20.02.21 with a price of €23.36. The price for Minerva Neurosciences Inc. massively increased, which is bad news for the SELL prediction by geldnutzer. geldnutzer has a follow-up prediction for Minerva Neurosciences Inc., but this time predicts that Minerva Neurosciences Inc. is a Buy. geldnutzer has 50% into this predictionMinerva Neurosciences (NASDAQ: NERV) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients suffering from neuropsychiatric disorders. With a primary emphasis on central nervous system diseases such as schizophrenia, major depressive disorder, insomnia, and Parkinson's, Minerva Neurosciences is committed to addressing unmet medical needs and advancing the understanding of the underlying biology of these conditions. Utilizing a strong research and development platform, the company aims to create a diversified portfolio of novel therapies that have the potential to significantly improve patients' quality of life and help them lead more fulfilling lives.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Minerva Neurosciences Inc. | - | - | - | - |
| iShares Core DAX® | -1.670% | -1.001% | 10.864% | 12.563% |
| iShares Nasdaq 100 | -4.184% | -1.145% | 37.458% | 41.078% |
| iShares Nikkei 225® | -4.967% | -5.783% | 18.828% | 0.655% |
| iShares S&P 500 | -2.834% | -0.572% | 25.875% | 39.960% |
According to geldnutzer what are the pros and cons of Minerva Neurosciences Inc. for the foreseeable future?
Pros
Standard Investments for future growth
Higher EBIT margin than peer group
Fair valuation
Good culture
Innovative
Growths faster than the competition
Differentiated customer and product portfolio
Top 10 in its market
Known brand
Future proof or reliable business model
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Normal challenges to pay loans and raise capital
Capable Management
Cons
Very low/no dividend yield expected
ROE lower than 10% per year
Few uniques
Sustainability is little important
Higher risks for its business
Significant cyclical dependencies
Comments by geldnutzer for this prediction
In the thread Minerva Neurosciences Inc. diskutieren
In the thread Trading Minerva Neurosciences Inc.
Current prediction by geldnutzer for Minerva Neurosciences Inc.
Minerva Neurosciences Inc.
Start price
Target price
Perf. (%)
€5.88
19.05.23
19.05.23
€7.00
19.05.24
19.05.24
-61.56%
05.04.24
05.04.24
Standard Investments for future growth
Higher EBIT margin than peer group
Very low/no dividend yield expected
ROE lower than 10% per year
Stopped prediction by geldnutzer for Minerva Neurosciences Inc.
Minerva Neurosciences Inc.
Start price
Target price
Perf. (%)
€3.19
11.06.22
11.06.22
€1.60
11.06.23
11.06.23
84.40%
19.05.23
19.05.23
Standard Investments for future growth
Higher EBIT margin than peer group
Very low/no dividend yield expected
ROE lower than 10% per year
Minerva Neurosciences Inc.
Start price
Target price
Perf. (%)
€4.81
14.03.22
14.03.22
€6.40
14.03.23
14.03.23
-33.68%
11.06.22
11.06.22
Standard Investments for future growth
Higher EBIT margin than peer group
Very low/no dividend yield expected
ROE lower than 10% per year
Minerva Neurosciences Inc.
Start price
Target price
Perf. (%)
€5.39
30.01.22
30.01.22
€4.00
30.01.23
30.01.23
-10.83%
14.03.22
14.03.22
Standard Investments for future growth
Higher EBIT margin than peer group
Very low/no dividend yield expected
ROE lower than 10% per year
Minerva Neurosciences Inc.
Start price
Target price
Perf. (%)
€6.41
20.12.21
20.12.21
€7.20
20.12.22
20.12.22
-15.91%
30.01.22
30.01.22
Standard Investments for future growth
Higher EBIT margin than peer group
Very low/no dividend yield expected
ROE lower than 10% per year
Minerva Neurosciences Inc.
Start price
Target price
Perf. (%)
€16.08
24.06.21
24.06.21
€4.80
24.06.22
24.06.22
-60.12%
20.12.21
20.12.21
Standard Investments for future growth
Higher EBIT margin than peer group
Very low/no dividend yield expected
ROE lower than 10% per year
Minerva Neurosciences Inc.
Start price
Target price
Perf. (%)
€18.77
11.06.21
11.06.21
€23.20
11.06.22
11.06.22
-14.32%
24.06.21
24.06.21
Standard Investments for future growth
Higher EBIT margin than peer group
Very low/no dividend yield expected
ROE lower than 10% per year
Minerva Neurosciences Inc.
Start price
Target price
Perf. (%)
€15.25
06.05.21
06.05.21
€18.40
06.05.22
06.05.22
23.09%
11.06.21
11.06.21
Standard Investments for future growth
Higher EBIT margin than peer group
Very low/no dividend yield expected
ROE lower than 10% per year
Minerva Neurosciences Inc.
Start price
Target price
Perf. (%)
€23.36
20.02.21
20.02.21
€26.40
20.02.22
20.02.22
-34.73%
06.05.21
06.05.21
Standard Investments for future growth
Higher EBIT margin than peer group
Very low/no dividend yield expected
ROE lower than 10% per year
Minerva Neurosciences Inc.
Start price
Target price
Perf. (%)
€23.20
13.10.20
13.10.20
€19.20
04.11.21
04.11.21
-28.28%
22.12.20
22.12.20
Standard Investments for future growth
Higher EBIT margin than peer group
Very low/no dividend yield expected
ROE lower than 10% per year
Minerva Neurosciences Inc.
Start price
Target price
Perf. (%)
€22.56
15.08.20
15.08.20
€16.00
13.10.20
13.10.20
2.84%
13.10.20
13.10.20
Standard Investments for future growth
Higher EBIT margin than peer group
Very low/no dividend yield expected
ROE lower than 10% per year
Minerva Neurosciences Inc.
Start price
Target price
Perf. (%)
€25.12
03.08.20
03.08.20
€32.00
15.08.20
15.08.20
-10.19%
15.08.20
15.08.20
Standard Investments for future growth
Higher EBIT margin than peer group
Very low/no dividend yield expected
ROE lower than 10% per year
Minerva Neurosciences Inc.
Start price
Target price
Perf. (%)
€24.48
25.07.20
25.07.20
€16.00
03.08.20
03.08.20
2.61%
03.08.20
03.08.20
Standard Investments for future growth
Higher EBIT margin than peer group
Very low/no dividend yield expected
ROE lower than 10% per year